However, enzalutamide was also capable of increasing the sensitivity of MDA MB 231 (ER-AR-) cells to CEA-specific CTL-mediated lysis compared to vehicle-treated tumor cells (P < 0.05, Figure 3C). The gene discussed is CEACAM5; the disease is neoplasm.